FUJIFILM Diosynth Biotechnologies
Thousand Oaks, CA
Research Triangle Park, NC
College Station, TX
Holly Springs, NC
About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies is an industry leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting our partners in the biopharmaceutical industry with the development and production of their biologic, vaccines and gene therapies.
With over 30 years of experience in process development and cGMP manufacturing, a dedicated staff of over 2,000 and a reputation for excellent customer service, flexibility and responsiveness, we’ve become a trusted partner to some of the most prominent biotech developers and pharmaceutical companies in the industry.
Our Process Development experience includes the development of processes for molecules expressed via fermentation (e.g., E. coli, P. pastoris), cell culture systems including CHO, HEK, Vero, MDCK, EB66 and insect cells, and from transgenic sources.
Our network expands within five development and manufacturing facilities located in Teesside, United Kingdom; Research Triangle Park, North Carolina, USA; College Station, Texas, Thousand Oaks CA USA and Hillerød, Denmark.
Join Us - We are Hiring!
61 articles with FUJIFILM Diosynth Biotechnologies
The new process development and manufacturing facility will focus on viral vectors and advanced therapies. It is the third location for Diosynth’s CDMO viral vector services.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
Less than one week after forging a vaccine manufacturing agreement with Novavax, FUJIFILM Diosynth Biotechnologies announced its College Station, Texas facility was selected by the federal government to support COVID-19 vaccine candidate manufacturing.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate
Novavax, Inc. announced an agreement to manufacture bulk drug substance for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.
With this capital investment, the site will be able to double its current drug substance manufacturing capacity and enhance its existing assembly operations. Production lines for bulk drug substance will be expanded, and development will begin on a new fill/finish production line.
Fujifilm to invest 100 billion yen (928 million USD) to expand its large scale biologics production facility in Denmark
FUJIFILM Corporation will make a major capital investment of approximately 100 billion yen in the Denmark site of FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization for biologics and advanced therapies.
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
Collaboration includes Development of Manufacturing Processes and to Supply Clinical Trial Material to Support Tonix’s Development of TNX-1800
FUJIFILM Diosynth Biotechnologies teams with COVID-19 Therapeutics Accelerator to reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies
- FUJIFILM Diosynth Biotechnologies, a world leading biologics-Contract Development and Manufacturing Organization (CDMO), today announced that it will reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator. The Therapeutics Accelerator is an initiative launched by the Bill & Meli
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
BioSpace Movers & Shakers, March 13
3/13/2020Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.
FUJIFILM Diosynth Biotechnologies Breaks Ground On A New BioCampus At Its Billingham, UK Location
FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, held a ground breaking ceremony on March 10, 2020 signalling commencement of construction of the company's new BioCampus at its Billingham, UK location.
FUJIFILM Diosynth Biotechnologies Named A Top Ten Healthiest Employer Nationally
Healthiest 100™ recognizes FUJIFILM Diosynth Biotechnologies as a top ten healthiest employer in nation
The new facility, which could be open by the end of 2021, will be supported by Harvard University, Massachusetts Institute of Technology, GE Healthcare Life Sciences, Alexandria Real Estate Equities and FUJIFILM Diosynth Biotechnologies.
FUJIFILM Diosynth Biotechnologies Announces $55 Million USD Investment To Expand Gene Therapy Development Capabilities
FUJIFILM Diosynth Biotechnologies will be expanding its gene therapy process and analytical development capabilities with the addition of new dedicated laboratories [14-November-2019] COLLEGE STATION, Texas , Nov. 14, 2019 /PRNewswire/ -- FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics Contract Development and Manufacturing Organization (CDMO) has
FUJIFILM Diosynth Biotechnologies Named A 2019 Healthiest Employer
FUJIFILM Diosynth Biotechnologies receives top honors in Triangle Business Journal's 2019 Healthiest Employers Awards
Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System
FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
AT BIO 2018 FUJIFILM ANNOUNCES THE OPENING OF CAMBRIDGE COLLABORATION CENTER TO EXPAND ITS FOOTPRINT
FUJIFILM Diosynth Biotechnologies (Fujifilm), today announced the opening of its Cambridge Collaboration Center.
Fujifilm Announces The Expansion Of Its Fill Finish Services To Include Late Phase And Commercial Production Of Gene Therapies And Viral Vaccines To Become An End To End Solutions Provider
FUJIFILM Diosynth Biotechnologies(Fujifilm), has announced the extension of its gene therapy and viral vaccine Fill/Finish.
Bio-Ess Laboratories And Fujifilm Diosynth Biotechnologies Find That Cell-Ess Media Supplement Improves Viral Production For Vaccine